Starpharma
(ASX:SPL) have released impressive results for their DEP irinotecan nanoparticle formulation for colon cancer.
The formulation showed significant efficacy and safety benefits over leading colorectal cancer drugs Camptosar and Erbitux.
Irinotecan (Camptosar®) is used as a component of first line therapy for the treatment of CRC, which is one of the most common cancers in the world, affecting more than 1 million individuals annually and is the third-leading cause of cancer-related death.
Starpharma
(ASX:SPL) are trading 5.1 per cent higher at $1.36.
